Pediatric Smoflipid Therapy: Patient Response and Safety Concerns.

CONCLUSION: In our patient population Smoflipid therapy led to cholestasis resolution in patients with lower direct bilirubin or less severe IFALD. Use of Smoflipid is also associated with significant safety concerns and its use should be coupled with close monitoring in pediatric patients, particularly in neonates. This article is protected by copyright. All rights reserved. PMID: 32458457 [PubMed - as supplied by publisher]
Source: JPEN Journal Of Parenteral And Enteral Nutrition - Category: Nutrition Authors: Tags: JPEN J Parenter Enteral Nutr Source Type: research